About the Guest
Vijit Sabnis is the co-founder and CEO of Adaptyx Biosciences, a Stanford spinout developing wearable technology for continuous molecular monitoring. Over the past 20 years, he has worked at the intersection of deep technology as an inventor, founder, and investor. Previously, he was Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.
Interview Summary
After spending years investing in frontier healthcare technologies, Vijit became convinced that continuous molecular sensing had reached an inflection point, where advances in AI, consumer wearables, and digital health could unlock the value of continuous biochemical data beyond continuous glucose monitoring (CGM) devices.
Today, most molecular biomarkers are measured through occasional blood draws, saliva samples, or urine tests, providing only isolated snapshots of biological processes that often change throughout the day. Adaptyx aims to replace those snapshots with continuous biochemical data collected from dermal interstitial fluid using programmable, DNA-based molecular switches embedded in a wearable patch. The company's first clinical focus is cortisol, a hormone typically measured using only a handful of static tests despite its dynamic daily rhythm and broad role across multiple physiological systems.
Beyond cortisol, Adaptyx is building a programmable sensing platform designed to continuously measure hormones, drugs, electrolytes, and other biomarkers.
Founded in 2022, Adaptyx holds an exclusive license to nine Stanford patents covering its core technology and has filed 18 additional patents. The company has raised $23 million in seed financing and recently presented its first-in-human cortisol data. It is initially pursuing FDA clearance for clinical applications while also exploring broader consumer health applications.
Top Takeaways
Look for signals that an idea can become a company. Medtech ideas with startup potential don't just solve a single problem — they unlock multiple clinical applications, benefit from broader technology and market trends, and become more valuable as the surrounding ecosystem evolves. For platform plays, choose an initial indication with a significant clinical need where your technology offers an advantage over existing approaches.
When spinning technology out of academia, redesign the learning process first. Academic research is optimized for discovery, not startup-speed iteration. One of the most difficult challenges in any early-stage venture is learning and iterating rapidly. Standardizing development workflows, automating repeatable work, and building tools that accelerate experimentation can compress learning cycles and make promising academic research commercially viable.
Build the adoption strategy into the product. New technology succeeds only when it's easy to integrate into existing care pathways. Design user experiences around the needs of each audience, presenting new data in ways that reduce interpretation burden and make it easy to act on. As new healthcare platforms emerge, consider how different partnerships can help bring those products to market more effectively.
Sponsors
FastWave Medical: Named MD+DI's Company of the Year, FastWave is one of the hottest medtech startups in the cardiovascular space. See how you can invest here.
Fundraising Cohort: Planning to raise capital for your startup? This live, 4-week workshop, led by Scott Nelson, is designed to help founders and CEOs tell a sharper story, get investor meetings that matter, and close real capital. Join the waitlist here.
